Jefferies analyst Andrew Tsai reiterated a Buy rating and $100.00 price target on BridgeBio Pharma (NASDAQ: BBIO).

The analyst comments "Net-net, $1B+ peak sales seems reasonable, and we model $600M+ in the US. (1) Per BBIO, the LGMD2I/R9 oppty could include 7,000 US+EU patients, which mgmt frames as a $1B oppty+ (subsequently updated from $600M+ post (+) interim Phase III results). We think the robust Phase III outcome measures warrant a pricing premium above our current $350K+ estimate. (2) Based on initial KOL checks, we BBP-418 will garner a meaningfully high market share (no other therapies). (3) In 2026, BBP-418 will expand into Fukuyama and LGMD2M/2U - two muscle dystrophies with a similar aDG pathology."

For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.

Shares of BridgeBio Pharma closed at $69.70 yesterday.